Brickell Biotech regains compliance with Nasdaq, avoids delisting

BOULDER — A reverse stock split has helped Boulder-based Brickell Biotech Inc. (Nasdaq: BBI) regain compliance with the Nasdaq stock market and avoid delisting.

Brickell said Wednesday that it had received formal notice from Nasdaq that it had regained compliance with the minimum-bid-price requirement for continued listing.

A hearing that was scheduled to review its listing has been canceled, and “Brickell’s common stock will continue to be listed and traded on Nasdaq,” the company said.

SPONSORED CONTENT

How Platte River Power Authority is accelerating its energy transition

Platte River Power Authority, the community-owned wholesale electricity provider for Northern Colorado, has a history of bold initiatives.

Brickell received a delisting notice from Nasdaq in June because its stock price had dropped below the minimum threshold of $1 for more than 30 consecutive days.

Brickell requested a hearing on the delisting and in the meantime scheduled a shareholders meeting to consider a 1-for-45 reverse stock split.

Shareholders approved the reverse stock split June 30, and the stock split became effective July 5.

The 1-for-45 reverse stock split reduced the number of outstanding shares of Brickell common stock from about 121.1 million shares to about 2.7 million shares.

Brickell’s stock closed up 9.5% Wednesday at $3.23 per share, up 28 cents.